Merck KGaA (OTCMKTS:MKKGY) Stock Rated “Hold” by Sell-Side Analysts

Shares of Merck KGaA (OTCMKTS:MKKGY – Get Free Report) have received an average recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation.

MKKGY has been the topic of several analyst reports. Zacks Research lowered Merck KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. UBS Group downgraded Merck KGaA from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Finally, HSBC raised shares of Merck KGaA to a “hold” rating in a research report on Monday, July 6th.

Get Merck KGaA alerts:

Check Out Our Latest Stock Analysis on Merck KGaA

Merck KGaA Trading Up 1.6%

Shares of OTCMKTS:MKKGY opened at $30.64 on Tuesday. The business’s 50 day simple moving average is $31.82 and its 200 day simple moving average is $29.67. Merck KGaA has a 1 year low of $23.73 and a 1 year high of $34.19. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.69 and a quick ratio of 1.09. The company has a market capitalization of $19.80 billion, a P/E ratio of 15.79, a P/E/G ratio of 2.86 and a beta of 0.96.

About Merck KGaA

(Get Free Report)

Merck KGaA is a Germany-based science and technology company headquartered in Darmstadt. Founded in 1668, it is one of the world’s oldest pharmaceutical and chemical businesses. Merck KGaA operates independently from the U.S.-based Merck & Co, Inc, which uses the name MSD in markets outside the United States and Canada.

The company operates through three primary business sectors: Life Science, Healthcare and Electronics. Its Life Science business supplies laboratory products, research tools, bioprocessing equipment and services used by academic institutions, pharmaceutical manufacturers and other industrial customers.

See Also

• Five stocks we like better than Merck KGaA
• Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
• Paychex Plunges, Providing the Entry Investors Have Been Waiting For
• The Case for Buying High-Yield General Mills Just Strengthened
• SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.